Core Viewpoint - The company anticipates gradual improvement in performance in Q2 2025 and the second half of the year, following the end of inventory destocking by downstream customers in the home respiratory device component sector [3]. Group 1: Home Respiratory Devices and Cochlear Implants - The company's core business involves the development, manufacturing, and sales of home respiratory devices and cochlear implant components [3]. - In 2024, the company expects a return to normal growth rates for home respiratory device component orders, supported by the Malaysian base potentially avoiding tariff risks, which is expected to drive long-term revenue growth [3]. - Revenue from cochlear implant components is showing steady growth, and new product component revenues are rapidly increasing, indicating effective diversification in business segments [3]. - Due to the impact of the Spring Festival on Q1 2025, revenue growth has slowed compared to the full year of 2024, but performance is expected to improve gradually as order deliveries resume [3]. Group 2: Blood Glucose Management and Production Expansion - The company has made breakthroughs in core technologies such as precision molds and liquid silicone, focusing on products like disposable injection pens, continuous glucose monitoring (CGM) devices, and insulin patch pumps [4]. - Collaborations with global medical device leaders are ongoing in the fields of blood glucose management, IVD diagnostics, and cardiovascular devices [4]. - A fully automated production project for insulin injection pens developed for international clients has achieved large-scale production in 2024 [4]. - The company has completed the core R&D work for its self-designed "Beautiful Pen," which includes three major technology directions [4]. - The Malaysian production base has successfully completed the first two phases of capacity construction, with the third phase expected to be operational by the end of 2025 [4]. Group 3: Stock Incentive Plan - The company has announced a stock incentive plan for 2025, granting a total of 5 million shares to no more than 304 core employees, representing 1.23% of the total share capital [5]. - The performance assessment for the stock incentive plan is based on revenue or net profit for 2023, with target growth rates for 2025-2027 set at no less than 56.25%, 95.31%, and 144.14% respectively [5]. - The triggering growth rates for 2025-2027 are set at no less than 44.00%, 72.80%, and 107.36% respectively, reflecting the company's confidence in long-term growth [5].

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 跟投。 宝聚禾医疗完成战略融资，并计划启动GMP注射笔智能工厂的设计，规划产能超亿支。 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 近日， 宝聚禾（苏州）医疗科技有限公司 （以下简称" 宝聚禾医疗"） 宣布 完成战略融资 本轮融资由 蒲公英创投、信达诺成创投领投，信奇产投、蒲公英江南创投等机构以及浙江江南等产业投资人 。 # 产品与技术 宝聚禾医疗专注于大健康医疗"自我给药装置"的工艺研究，并提供整体解决方案。在GLP-1类药物市场持续升温的背景下，宝聚禾医疗凭借其独特的产品 优势和技术积累，成功研发出 LoonGBIOPen ® 、Beinghigher® 等多款一次性注射笔，并与多家药厂进行研发验证配套。这些注射笔产品不仅 拥有自主发明专利，还适配于所有预灌充注射类药物，应用场景极为广泛。 产品精度全面达到ISO11608国际标准要求， 核心产品 LoonGBIOPen ® 一次性注射笔 ：主要用于糖尿病、肥胖症等慢性疾病的治疗， 注射精度达到国际标准ISO11608要求。 Beinghigh ...